Insider Selling: Natera, Inc. (NASDAQ:NTRA) CFO Sells 495 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 495 shares of the business’s stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $141.28, for a total value of $69,933.60. Following the completion of the sale, the chief financial officer owned 71,249 shares of the company’s stock, valued at approximately $10,066,058.72. This trade represents a 0.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, July 22nd, Michael Burkes Brophy sold 920 shares of Natera stock. The stock was sold at an average price of $139.58, for a total value of $128,413.60.
• On Thursday, July 24th, Michael Burkes Brophy sold 755 shares of Natera stock. The stock was sold at an average price of $139.50, for a total value of $105,322.50.
• On Monday, July 21st, Michael Burkes Brophy sold 602 shares of Natera stock. The shares were sold at an average price of $139.29, for a total value of $83,852.58.
• On Monday, April 28th, Michael Burkes Brophy sold 2,018 shares of Natera stock. The shares were sold at an average price of $152.18, for a total value of $307,099.24.

Natera Price Performance

NASDAQ NTRA opened at $141.07 on Friday. The firm has a market cap of $19.26 billion, a P/E ratio of -95.97 and a beta of 1.73. The stock’s 50-day moving average is $159.07 and its 200-day moving average is $157.34. Natera, Inc. has a one year low of $92.14 and a one year high of $183.00.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.09. The company had revenue of $501.83 million for the quarter, compared to analyst estimates of $446.68 million. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. Natera’s revenue was up 36.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.56) earnings per share. Equities analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on NTRA shares. Barclays upped their price target on Natera from $160.00 to $190.00 and gave the company an “overweight” rating in a research report on Friday, May 9th. Piper Sandler boosted their price objective on Natera from $205.00 to $210.00 and gave the stock an “overweight” rating in a research note on Thursday, May 15th. Wall Street Zen lowered Natera from a “hold” rating to a “sell” rating in a research note on Saturday, May 17th. Finally, UBS Group upped their price target on Natera from $211.00 to $218.00 and gave the company a “buy” rating in a research note on Friday, May 9th. One investment analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $184.63.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. HighPoint Advisor Group LLC grew its holdings in shares of Natera by 30.8% during the first quarter. HighPoint Advisor Group LLC now owns 1,986 shares of the medical research company’s stock worth $308,000 after buying an additional 468 shares in the last quarter. Amalgamated Bank grew its holdings in shares of Natera by 9.8% during the first quarter. Amalgamated Bank now owns 8,293 shares of the medical research company’s stock worth $1,173,000 after buying an additional 740 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Natera by 32.3% during the first quarter. GAMMA Investing LLC now owns 848 shares of the medical research company’s stock worth $120,000 after buying an additional 207 shares in the last quarter. Teza Capital Management LLC bought a new position in Natera in the fourth quarter valued at approximately $221,000. Finally, Asset Management One Co. Ltd. bought a new position in Natera in the first quarter valued at approximately $6,753,000. 99.90% of the stock is currently owned by institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.